Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome
Clinical trial NCT06050122 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06050122
- Sponsor
- Sol-Gel Technologies, Ltd.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-03-17
- Primary completion
- 2026-10-01
- Enrollment
- 140
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.